Comparison and switching
The most important comparison point is approval status: semaglutide and tirzepatide have approved products for specific uses, while retatrutide remains investigational.
Retatrutide, tirzepatide, and semaglutide should not be treated as interchangeable. They differ by receptor targets, evidence, approved labels, and medical-supervision requirements.
These references frame the evidence base behind this topic. They are not medical advice, approval, or instructions for using retatrutide outside a clinical trial.
Short source quoteagonist of the GIP, GLP-1, and glucagon receptors
Jastreboff et al., NEJM 2023 retatrutide phase 2 obesity trial
This peer-reviewed phase 2 paper is the anchor for retatrutide mechanism language. It does not make retatrutide approved or publicly available.
Short source quoterandomised, double-blind, placebo and active-controlled
Rosenstock et al., Lancet 2023 retatrutide phase 2 type 2 diabetes trial
The type 2 diabetes phase 2 paper helps separate controlled clinical research from online self-use claims.
Short source quoterandomized, double-blind, placebo-controlled trial
Sanyal et al., Nature Medicine 2024 retatrutide MASLD phase 2a trial
The MASLD substudy adds peer-reviewed evidence for metabolic research context, but it is still not public-use approval.
Short source quoteObesity is a chronic disease
Jastreboff et al., NEJM 2022 SURMOUNT-1 tirzepatide obesity trial
This tirzepatide trial is useful comparison context, but tirzepatide labels and prescriber review still govern real treatment decisions.
Short source quoteObesity is a global health challenge
Wilding et al., NEJM 2021 STEP 1 semaglutide obesity trial
This semaglutide trial provides approved-GLP-1 context for comparison and alternatives pages, not retatrutide dosing guidance.
Use comparison pages to prepare clinician questions about approved treatment paths, not to self-switch to investigational products.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. Retatrutide is investigational and is not FDA approved. FDA-approved options such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.
Public record review
Submit a public page, correction, or observation for documentation review. Submissions are evaluated for public-record value only, not to help people obtain products.
